3. Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022;
4. Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc);
5. Informed consent form signed by the patient and their guardian.
You may not be if
1. ESC 2022 Group II-V PAH;
2. Poor right ventricular function: RVEF \< 25% or RVFAC \< 20%;
3. Deteriorated general condition: requiring ICU resuscitation or ECMO assistance;
4. Pulmonary artery pressure/main arterial pressure ratio \< 0.7;
5. Six-minute walk distance \< 150 meters (only applicable to patients aged 8 and above);
6. No significant improvement in RVEF under triple drug therapy.
Clareo Health | Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension
